Biophage awarded government accreditation for its Beryllium reference lab

    Biophage now operates the ONLY Beryllium lab officially certified by the
    Quebec Ministry of Health and Social Services

    MONTREAL, Sept. 11 /CNW Telbec/ - (TSX.V: BUG). Biophage Pharma Inc.
(Biophage) is very pleased to announce that it has obtained official
accreditation from the Quebec Ministry of Health and Social Services for its
Beryllium Reference Laboratory. This certification makes Biophage the ONLY
officially recognized lab qualified to conduct government approved screening
for Beryllium sensitization (BeLPT testing) in Quebec. Biophage secured the
certification by meeting strict government guidelines and demonstrating its
competence in the analysis and interpretation of BeLPT test results. Biophage
is now positioned to be the leading provider of BeLPT testing in Quebec and
Canada and is rapidly expanding its screening services to the United States,
which has only five laboratories offering BeLPT testing.
    The Quebec CSST survey entitled "Operation Beryllium" confirmed that
Beryllium is present in 2800 establisments in Quebec with a potential 100,000
beryllium exposed workers. In the United States, several studies reported that
around 800,000 workers were exposed to Beryllium. The major sectors are
foundries, aerospace and aeronautics sector, machine shops and scrap metal
shops, dentistry labs and recycling industries. It is also known that family
members of Beryllium exposed workers are also at risk of secondary exposure to
Beryllium dust brought home from the workplace on clothing.
    "This accreditation represents a significant milestone for Biophage and
puts us in the front seat far ahead of competition. It will also help us
accelerate the generation of revenues from this very lucrative market that
represents about $35 million in Quebec and $1.2 billion in the United States."
said Dr. Rosemonde Mandeville, President and Chief Executive Officer of
Biophage Pharma Inc. "Our objective is to reach the largest number of workers
in the aerospace industries and foundries in Canada and the United States, so
that they can benefit from this screening as quickly as possible," concluded
Dr. Mandeville.

    About Biophage Pharma Inc.

    Biophage is a Canadian biotechnology company focused on the development
of innovative phage-based products and technologies for the detection,
prevention and control of bacterial infections. Biophage operates three
divisions: (1) The Immunotox Labs division, which provides services in
Immunogenicity and Immunotoxicity, screening for Beryllium sensitization (the
BeLPT test) and exclusive MELISA(R) for the detection of sensitization to more
than 200 different allergens including metals, penicillin, gluten, pollens and
more recently Lyme disease (Boreliosis); (2) The Biosensors division for the
development and commercialization of Biosensors PDS(R); and (3) The
Therapeutics division for the prevention and control of bacterial
contaminations in the medical, veterinary and environment fields. Both the
Biosensor and Phage therapy programs have been structured to deliver an
environmentally safe solution for the early detection and rapid control of
deadly microorganisms. (;

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.
    %SEDAR: 00014714EF

For further information:

For further information: Biophage Pharma Inc.: Rosemonde Mandeville,
M.B., Ch.B., PhD., President and CEO, (514) 496-1488,; Beryllium Reference Lab: Dr Michel
Heyne, MD, Hematologist, Director, (514) 496-1453,; ImmunotoxLabs: Miguel Retamal, M.Sc.,
Director, (514) 496-4508,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890